Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: GlobeNewswire
ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows: Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic RatPresenter: Jolanta Skarbaliene, Ph.D.Format: Oral Presentation, Session IIDate, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT) Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoLPresenter: Markus Magerl, M.D.Format: Oral Presentation, Session VIIDate, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT) Title: Long-Term Safety and Efficacy of
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesGlobeNewswire
- Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference [Yahoo! Finance]Yahoo! Finance
- Pharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingGlobeNewswire
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsGlobeNewswire
PHVS
Earnings
- 11/13/24 - Miss
PHVS
Sec Filings
- 11/13/24 - Form 6-K
- 10/31/24 - Form 144
- 10/24/24 - Form 144
- PHVS's page on the SEC website